Test IMP (EDG-5506) without active substance

DRUG2 trials

Sponsors

Edgewise Therapeutics Inc.

Conditions

Becker Muscular DystrophyBecker Muscular Dystrophy (BMD)Limb-Girdle Muscular DystrophyMcArdle Disease

Phase 2

A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effect of EDG-5506 on Biomarker Response to Exercise in Adults with Becker Muscular Dystrophy, McArdle Disease, or Limb-Girdle Muscular Dystrophy

CompletedCTIS2022-500215-39-00

Edgewise Therapeutics Inc.Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, McArdle Disease

Start: 2022-12-06End: 2025-11-24Target: 21Updated: 2025-09-19

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy

Active, not recruitingCTIS2022-500090-13-00

Edgewise Therapeutics Inc.Becker Muscular Dystrophy (BMD)

Start: 2022-12-29Target: 81Updated: 2025-09-12